Literature DB >> 9531615

Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha.

P M Grimley1, H Fang, H Rui, E F Petricoin, S Ray, F Dong, K H Fields, R Hu, K C Zoon, S Audet, J Beeler.   

Abstract

Multiple biologic effects of interferon-alpha (IFN-alpha), including cell growth inhibition and antiviral protection, are initiated by tyrosine phosphorylation of STAT proteins. Although this signal pathway has been intensively investigated, the relevance of STAT signal persistence has received scant attention. Using paired isogenic lymphoma cells (Daudi), which either are sensitive or resistant to growth inhibition by IFN-alpha, we found comparable initial tyrosine phosphorylation of multiple STAT proteins; however, the phosphorylation durations and associated DNA-binding activities diverged. Phosphorylation and DNA-binding capacity of STAT1 decreased after 4 to 8 hours in resistant cells, as compared with 24 to 32 hours in sensitive cells, whereas phosphorylation of STAT3 and STAT5b was briefer in both lines. Functional significance of the prolonged STAT1 signal, therefore, was explored by experimental interruption of tyrosine phosphorylation, either by premature withdrawal of the IFN-alpha or deferred addition of pharmacologically diverse antagonists: staurosporine (protein kinase inhibitor), phorbol 12-myristate 13-acetate (growth promoter), or aurintricarboxylic acid (ligand competitor). Results indicated that an approximately 18-hour period of continued STAT1 phosphorylation was associated with growth arrest, but that antiviral protection developed earlier. These differences provide novel evidence of a temporal dimension to IFN-alpha signal specificity and show that duration of STAT1 activation may be a critical variable in malignant cell responsiveness to antiproliferative therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531615

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Authors:  Zohar Sachs; Raha A Been; Krista J DeCoursin; Hanh T Nguyen; Nurul A Mohd Hassan; Klara E Noble-Orcutt; Craig E Eckfeldt; Emily J Pomeroy; Ernesto Diaz-Flores; Jennifer L Geurts; Miechaleen D Diers; Diane E Hasz; Kelly J Morgan; Margaret L MacMillan; Kevin M Shannon; David A Largaespada; Stephen M Wiesner
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

2.  A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family.

Authors:  S Miersch; S Kuruganti; M R Walter; S S Sidhu
Journal:  Protein Eng Des Sel       Date:  2017-09-01       Impact factor: 1.650

Review 3.  Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.

Authors:  Patricia A Young; Sherie L Morrison; John M Timmerman
Journal:  Semin Oncol       Date:  2014-08-12       Impact factor: 4.929

4.  Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma.

Authors:  Asuka Nanbo; Kaori Inoue; Kumi Adachi-Takasawa; Kenzo Takada
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

5.  Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.

Authors:  Caiyun Xuan; Kristopher K Steward; John M Timmerman; Sherie L Morrison
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

6.  Noncytolytic clearance of sindbis virus infection from neurons by gamma interferon is dependent on Jak/STAT signaling.

Authors:  Rebeca Burdeinick-Kerr; Dhanasekaran Govindarajan; Diane E Griffin
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.

Authors:  Edmund A Rossi; David M Goldenberg; Thomas M Cardillo; Rhona Stein; Chien-Hsing Chang
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

8.  Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.

Authors:  F Romerio; A Riva; D Zella
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

9.  IFN-α/β-mediated NK2R expression is related to the malignancy of colon cancer cells.

Authors:  Huihui Xiang; Yujiro Toyoshima; Weidong Shen; Xiangdong Wang; Naoki Okada; Shuhei Kii; Ko Sugiyama; Toshihiro Nagato; Hiroya Kobayashi; Kazuho Ikeo; Shinichi Hashimoto; Mishie Tanino; Akinobu Taketomi; Hidemitsu Kitamura
Journal:  Cancer Sci       Date:  2022-05-31       Impact factor: 6.518

Review 10.  Insights into cytokine-receptor interactions from cytokine engineering.

Authors:  Jamie B Spangler; Ignacio Moraga; Juan L Mendoza; K Christopher Garcia
Journal:  Annu Rev Immunol       Date:  2014-12-10       Impact factor: 28.527

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.